138 completed, 18 unknown, 11 recruiting, 11 terminated. 187 Phase 2, 29 Phase 1, 26 Phase 3.
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Lisdexamfetamine For the Treatment of Conduct Disorder in Children Lidexamfetamine - Conduct Disorder | Phase 2 | Not yet recruiting | Orygen | 30 | 2027-02-01 | 2026-11-06 |
| Novel Approaches to Supporting Students With ADHD in Multi-Tiered Systems of Support Academic Competency Enhancement (ACE) classroom, School as Usual Classroom Supports - Attention Deficit Hyerpactivity Disorder | Phase 2 / Phase 3 | Not yet recruiting | Florida International University | 544 | 2027-01-01 | 2026-09-28 |
| A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD Fecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID - ADHD, ADHD - Attention Deficit Disorder With Hyperactivity | Phase 2 | Not yet recruiting | University of Calgary | 64 | 2026-08-31 | 2026-09-10 |
| A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) ALKS 7290, Placebo - Attention Deficit Disorder With Hyperactivity (ADHD) | Phase 2 | Recruiting | Alkermes, Inc. | 312 | 2026-08-10 | 2026-10-29 |
| Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) Experimental: Full-spectrum CBG oil 30 mg/mL, Placebo oil (MCT oil) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 60 | 2026-05-01 | 2026-05-18 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose, Placebo - Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 315 | 2025-09-03 | 2025-12-23 |
| Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression DEX IR tablets, DEX XL, Placebo - Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder | Phase 2 | Recruiting | Prof. Dr. Frank Behrens | 105 | 2025-05-15 | 2026-09-25 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 630 | 2025-04-30 | 2026-10-23 |
| Pathways 2 Success L2B, L2B + App, skills for success - Conduct Disorder, Oppositional Defiant Disorder | Phase 1 / Phase 2 | Recruiting | University of Minnesota | 120 | 2025-03-12 | 2026-04-13 |
| A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder NRCT-101SR, NRCT-202XR - ADHD | Phase 2 | Terminated | Neurocentria, Inc. | 2 | 2025-02-25 | 2026-01-15 |
| Dual-target iTBS for Youth With ADHD TMS - ADHD | Phase 1 / Phase 2 | Recruiting | Shanghai Mental Health Center | 15 | 2025-01-01 | 2025-07-24 |
| The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder Cannabigerol, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | University of Arkansas, Fayetteville | 67 | 2024-12-14 | 2026-11-09 |
| Black Seed Oil in ADHD Atomoxetine, Black Seed Oil Cap/Tab - ADHD | Phase 2 | Unknown | Ain Shams University | 60 | 2024-10-01 | 2024-08-09 |
| Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Sertraline, Placebo - Neurodevelopmental Disorders, Autism | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 130 | 2024-09-16 | 2026-07-27 |
| Extending the Reach of Evidence-based Practices to Support Student's Attention and Behavior Through Technology Collaborative Life Skills dHealth tool (CLS-D) - Control Condition, Intervention Condition | Phase 2 | Enrolling by invitation | San Diego State University | 216 | 2024-09-01 | 2026-04-08 |
| The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD Oral CBD oil enriched with terpenes, Oral Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Unknown | Bazelet Nehushtan LtD. | 120 | 2024-08-22 | 2024-08-23 |
| Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial Non-adaptive Floreo VR control, Floreo Virtual Reality application - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Recruiting | National Institute of Mental Health (NIMH) | 219 | 2024-03-15 | 2026-10-08 |
| Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes parental training in behavior management, Lisdexamfetamine, Methylphenidate - Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1 | Phase 2 | Recruiting | Medical University of Lodz | 150 | 2024-02-05 | 2024-11-29 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
Showing 20 of 187. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (175) · Conduct Disorder (11) · Substance-Related Disorders (8) · Depression (7) · Spasm (7) · Cocaine-Related Disorders (6) · Impulsive Behavior (5) · Autism Spectrum Disorder (4) · Alcoholism (3) · Anxiety Disorders (3) · Autistic Disorder (3) · Brain Injuries, Traumatic (3) · Neurodevelopmental Disorders (3) · Oppositional Defiant Disorder (3)
Mental Disorders (186) · Neurodevelopmental Disorders (184) · Behavior (21) · Nervous System Diseases (21) · Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (18) · Neurologic Manifestations (17) · Chemically-Induced Disorders (16) · Behavioral Symptoms (10) · Substance-Related Disorders (8) · Central Nervous System Diseases (7) · Neurobehavioral Manifestations (7) · Neuromuscular Manifestations (7) · Brain Diseases (6)
Methylphenidate (28) · Atomoxetine Hydrochloride (18) · Lisdexamfetamine Dimesylate (7) · pozanicline (7) · Amphetamine (6) · Dextroamphetamine (4) · SLI381 (4) · Sugars (4) · Tablets (4) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (3) · 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (2) · 5,10-dihydro-5-methylphenazine (2) · Capsules (2) · Dexmethylphenidate Hydrochloride (2) · Exercise (2)
New York State Psychiatric Institute (7) · Eli Lilly and Company (6) · AbbVie (prior sponsor, Abbott) (5) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · Shire (5) · Supernus Pharmaceuticals, Inc. (5) · Alcobra Ltd. (4) · Massachusetts General Hospital (4) · Abbott (3) · Aevi Genomic Medicine, LLC, a Cerecor company (3) · Children's Hospital Medical Center, Cincinnati (3) · Ironshore Pharmaceuticals and Development, Inc (3) · National Institute of Mental Health (NIMH) (3) · Neurocentria, Inc. (3) · New River Pharmaceuticals (3)
United States (111) · Canada (14) · Israel (13) · Japan (7) · Germany (6) · Taiwan (4) · Brazil (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · China (2) · France (2) · Iran (2) · Poland (2) · Puerto Rico (2)
Craig Surman, MD (4) · Frances R Levin, M.D. (3) · Ann Childress, M.D. (2) · Christian Fleischhaker, MD (2) · Earle Bain, MD (2) · Frances R Levin, MD (2) · Heather Boon, PhD (2) · Iris Manor, MD (2) · Klaus Hennighausen, MD (2) · Laura Gault, MD, PhD, MD (2) · Leigh J Beglinger, Ph.D. (2)
PMID 20732631, PMID 21156272, PMID 10385840, PMID 11514638, PMID 16041867, PMID 16102908, PMID 16481664, PMID 16890481, PMID 17284136, PMID 17631866, PMID 18469236, PMID 18544723, PMID 18632997, PMID 19849639, PMID 19877974, PMID 20048226, PMID 20215923, PMID 20406576, PMID 20445835, PMID 20445836, PMID 20445837, PMID 20680193, PMID 20869813, PMID 20973706, PMID 21265936, PMID 21356232, PMID 21476931, PMID 21597989, PMID 21748252, PMID 21807480, PMID 22024004, PMID 22170209, PMID 22313788, PMID 22372512, PMID 22519922, PMID 22795204, PMID 23106988, PMID 23115630, PMID 23290324, PMID 23344135, PMID 23660970, PMID 23738530, PMID 23856296, PMID 23933905, PMID 24043939, PMID 24117656, PMID 24375941, PMID 24493927, PMID 24523588, PMID 24664093
K23NS055733 (1), K24AA000301 (1), P30MH071478 (1), P50DA009236 (1), P50DA009262 (1), P50HD093074 (1), R01AA026859 (1), R01DA011444 (1), R01DA019233 (1), R01DA022217 (1), R01DA023652 (1), R01MH061563 (1), R01MH063272 (1), R01MH064707 (1), R01MH067949 (1)